[1]
|
M. Jerzak and P. Bischof, “Apoptosis in the First Trimester Human Placenta: The Role in Maintaining Privilege at the Matemal-Foetal Interface and the Trophoblast Remodeling,” The European Journal of Obstetrics & Gynecology and Reproductive Biology, Vol. 100, 2002, pp. 138- 142. http://dx.doi.org/10.1016/S0301-2115(01)00431-6
|
[2]
|
D. Michael and M. Oren, “The p53-Mdm2 Module and the Ubiquitin System,” Cancer Biology, Vol. 13, 2003, pp. 49-58. http://dx.doi.org/10.1016/S1044-579X(02)00099-8
|
[3]
|
G. Beckman, R. Birgander, A. Sjalander, et al., “Is p53 Polymorphism Maintained by Natural Selection?” Human Heredity, Vol. 44, 1994, pp. 266-270.
http://dx.doi.org/10.1159/000154228
|
[4]
|
L. V. J. Schaffer, C. Breymann, M. Gassmann and H. H. Marti, “Preserved Placental Oxygenation and Development during Severe Systemic Hypoxia,” The American Journal of Physiology Regulatory, Integrative and Comparative Physiology, Vol. 290, No. 3, 2006, pp. 844-851.
http://dx.doi.org/10.1152/ajpregu.00237.2005
|
[5]
|
A. C. K. Ajakumar, “Expression, Ontogeny, and Regulation of Hypoxia-Inducible Transcription Factors in the Human Placenta,” Biology of Reproduction, Vol. 63, No. 2, 2000, pp. 559-569.
http://dx.doi.org/10.1095/biolreprod63.2.559
|
[6]
|
D. E. F. J. Ingber, “Mechanochemical Switching between Growth and Differentiation during Fibroblast Growth Factor-Stimulated Angiogenesis in Vitro: Role of Extracellular Matrix,” The Journal of Cell Biology, Vol. 109, No. 1, 1989, pp. 317-330.
|
[7]
|
M. D. L. D. Mueller, E. Garrett and R. N. Taylor, “Neutrophils Infiltrating the Endometrium Express Vascular Endothelial Growth Factor: Potential Role in Endometrial Angiogenesis,” Fertility and Sterility, Vol. 74, No. 1, 2000, pp. 107-112.
|
[8]
|
S. SK, “Angiogenesis and Implantation,” Human Reproduction, Vol. 15, No. S6, 2000, pp. 59-66.
|
[9]
|
L. O. A. Hefler, P. Husslein, C. Kainz and C. Tempfer, “Vascular Endothelial Growth Factor Serum Levels in Pregnancy and Preeclampsia,” Acta Obstetricia et Gynecologica Scandinavica, 2000, pp. 77-78.
|
[10]
|
H. H. R. W. Marti, “Angiogenesis in Ischemic Disease,” Vol. 82, 1999, pp. 44-52.
|
[11]
|
S. N. K. aishi, N. Kinukawa, H. Nakano and K. Sueishi, “Immunohistochemical Localization of Vascular Endothelial Growth Factor in the Human Placenta,” Placenta, Vol. 17, No. 2-3, 1996, pp. 111-121.
|
[12]
|
P. C. O. Vuorela, M. Tulppala and E. Halmesmaki, “VEGF, Its Receptors and the Tie Receptors in Recurrent Miscarriage,” Molecular Human Reproduction, Vol. 6, No. 3, 2000, pp. 276-282.
|
[13]
|
G. J. H. J. Burton and A. L. Wetson, “Maternal Arterial Connections to the Placectal Intervil Lous Space during the First Trimester of Human Pregnancy,” American Journal of Obstetrics & Gynecology, Vol. 181, 1999, p. 71.
|
[14]
|
H. D. Z. J. Skinner, J. Fang, F. Agani and B. H. Jiang, “Vascular Endothelial Growth Factor Transcriptional Activation Is Mediated by Hypoxia-Inducible Factor Lalpha, HDM2, and p74S6K1 in Response to Phosphatidylinositol 3-Kinase/AKT Signaling,” The Journal of Biological Chemistry, Vol. 279, No. 44, 2004, pp. 45643-51.
|
[15]
|
M. Thomas, A. Kalita, S. Labrecque, et al., “Two Polymorphic Variants of Wild-Type p53 Differ Biochemically and Biologically,” Molecular and Cellular Biology, 1999, pp. 1092-1100.
|
[16]
|
P. Dumont, J. I. Leu, A. Cr. Della Pietra, et al., “The Codon 72 Polymorphic Variants of p53 Have Markedly Different Apoptotic Potential,” Nature Genetics, Vol. 33, 2003, pp. 357-365.
|
[17]
|
G. L. Bond, W. Hu, E. E. Bond, et al., “A Single Nucleotide Polymorphism in the MDM2 Promoter Attenustes the p53 Tumor Suppressor Pathway and Accelerates Tumor Formation in Humans,” Cell, Vol. 119, 2004, pp. 591- 602.
|
[18]
|
D. Michael and M. Oren, “The p53-Mdm2 Module and the Ubiquitin System,” Cancer Biology, Vol. 13, 2003, pp. 49-58.
|
[19]
|
Y. Hong, X. Zhang, et al., “The Role of p53 and MDM2 Polymorphisms in the Risk of Esophagel Squamaous Cell Carcinoma,” Cancer Research, Vol. 65, 2005, pp. 9582- 9587.
|